2024
DOI: 10.1111/iju.15458
|View full text |Cite
|
Sign up to set email alerts
|

Editorial Comment to Survival beyond cabazitaxel for metastatic castration‐resistant prostate cancer

Yoshiyuki Yamamoto,
Norio Nonomura

Abstract: Phase III study comparing a reduced dose of cabazitaxel (20 mg/m 2 ) and the currently approved dose (25 mg/m 2 ) in postdocetaxel patients with metastatic castration-resistant prostate cancer-PROSELICA.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 5 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?